Vitaline® Herbal Formulas for 30 yrs.
Pharmaceutical Grade Supplements Manufactured by Health Care Professionals. Formulas Prescribed by thousands of doctors worldwide.
Integrative Therapeutics Inc. Products
(CoQ10) can improve kidney function and reduce the need for dialysis.
Coenzyme Q10 Beneficial for People with Kidney Failure By Alan R. Gaby, MD Healthnotes Newswire (July 17, 2003)Supplementing with coenzyme Q10 (CoQ10) can improve kidney function and reduce the need for dialysis in people with severe, chronic kidney (renal) failure, according to a study in the Journal of Nutritional and Environmental Medicine (2003;13:13–22). If this study is confirmed, CoQ10 therapy will represent a major breakthrough in the treatment of a disorder that is both debilitating and a significant drain on our healthcare resources.
In severe, chronic renal failure, the kidneys lose their capacity to excrete waste products of metabolism and other toxins. Consequently, these substances accumulate in the body, leading to various problems such as fatigue, loss of appetite, anemia, disorders of the nervous system, heart disease, and ultimately death. Common causes of chronic renal failure include diabetes, hardening of the arteries (atherosclerosis), and high blood pressure.
People with advanced renal failure are usually treated three or more times per week by a procedure called dialysis, in which a machine is used to filter the toxins from the blood. While dialysis can prolong life in people with advanced renal failure, it is associated with a number of adverse effects, including low blood pressure, infection, and worsening heart disease. In addition, dialysis is expensive, costing more than $50,000 per year at some centers. Any treatment that has the potential to improve kidney function and reduce the need for dialysis would be a significant advance.
In the new study, 97 people (average age, 48 years) with chronic renal failure were randomly assigned to receive a placebo or 60 mg of CoQ10 by mouth three times per day for 12 weeks. Among the 45 participants who were already receiving dialysis, supplementation with CoQ10 resulted in an improvement in various measures of kidney function, including serum creatinine (29% improvement) and blood urea nitrogen (9% improvement). In contrast, kidney function tended to worsen in the placebo group, and the differences between CoQ10 and placebo were statistically significant. CoQ10 also produced significant improvements relative to placebo among the participants who were not receiving dialysis. By the end of the study, the number of people requiring dialysis had decreased from 21 to 12 in the CoQ10 group, but remained unchanged at 24 in the placebo group.
These results suggest that treatment with CoQ10 improves kidney function and reduces the need for dialysis in people with chronic renal failure. Because CoQ10 has the potential to revolutionize the treatment of chronic renal failure, a large-scale, long-term study should be initiated as soon as possible.
Alan R. Gaby, MD, an expert in nutritional therapies, testified to the
White House Commission on CAM upon request in December 2001. Dr. Gaby served
as a member of the Ad-Hoc Advisory Panel of the National Institutes of Health
Office of Alternative Medicine. He is the author of Preventing and Reversing
Osteoporosis (Prima, 1994), and co-author of The Natural Pharmacy, 2nd Edition
(Healthnotes, Prima, 1999),
CoQ10 (Coenzyme Q10) and Renal Failure Chronic renal failure (CRF) is the progressive loss of kidney function.
Chronic Renal Insufficiency (CRI) is the early stage, when the kidneys
no longer function properly but do not yet require dialysis.
CoQ10 was studied in a small pilot study involving 21 patients with chronic renal failure. Researchers administered CoQ10 to 11 of the subjects while 10 received a placebo capsule. To be included in the study patients had to have a creatinine level of 5 mg/dl or above. After 4 weeks, the subjects receiving CoQ10 had significant decreases in serum creatinine and urea while creatinine clearance significantly increased. At the end of the 4 week study the number of patients on dialysis was significantly less in the CoQ10 group. 36.2% of the patients in the CoQ10 group were on dialysis at the end of the study while 90.0% of the placebo group were on dialysis at the end of the study.
An increase in blood antioxidant levels and a significant decrease in indicators
of oxidative stress were noted by the study group. (J Nutr Environ Med,
2000; 10: 281-288)
"Randomized, Double-Blind Placebo-Controlled Trial of Coenzyme Q10 in Chronic Renal Failure: Discovery of a New Role," Singh RB, Khanna HK, Niaz MA, J Nutr Environ Med, 2000;10:281-288.36843
All information is for informational purposes only, and not intended to diagnose, treat, cure or prevent any disease. No statements have been evaluated by the FDA. We always suggest talking to your physician concerning any questions you may have about supplement/drug interactions.